Eupraxia Pharmaceuticals Stock Current Ratio

Eupraxia Pharmaceuticals fundamentals help investors to digest information that contributes to Eupraxia Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eupraxia Pink Sheet. The fundamental analysis module provides a way to measure Eupraxia Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eupraxia Pharmaceuticals pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Eupraxia Pharmaceuticals Company Current Ratio Analysis

Eupraxia Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Current Ratio

 = 

Current Asset

Current Liabilities

More About Current Ratio | All Equity Analysis

Current Eupraxia Pharmaceuticals Current Ratio

    
  10.13 X  
Most of Eupraxia Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eupraxia Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Competition

In accordance with the recently published financial statements, Eupraxia Pharmaceuticals has a Current Ratio of 10.13 times. This is 248.11% higher than that of the Healthcare sector and 44.71% higher than that of the Biotechnology industry. The current ratio for all United States stocks is notably lower than that of the firm.

Eupraxia Current Ratio Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eupraxia Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eupraxia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eupraxia Pharmaceuticals by comparing valuation metrics of similar companies.
Eupraxia Pharmaceuticals is currently under evaluation in current ratio category among its peers.

Eupraxia Fundamentals

Currently Active Assets on Macroaxis

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Other Consideration for investing in Eupraxia Pink Sheet

If you are still planning to invest in Eupraxia Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eupraxia Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Commodity Directory
Find actively traded commodities issued by global exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules